VRCDF (Verici Dx) Beginning Cash Position : $2.65 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Beginning Cash Position?

Verici Dx's Beginning Cash Position for the quarter that ended in Jun. 2024 was $2.65 Mil.

Verici Dx's quarterly Beginning Cash Position declined from Jun. 2023 ($9.81 Mil) to Dec. 2023 ($5.25 Mil) and declined from Dec. 2023 ($5.25 Mil) to Jun. 2024 ($2.65 Mil).

Verici Dx's annual Beginning Cash Position declined from Dec. 2021 ($17.75 Mil) to Dec. 2022 ($10.34 Mil) and declined from Dec. 2022 ($10.34 Mil) to Dec. 2023 ($9.81 Mil).

Verici Dx Beginning Cash Position Historical Data

The historical data trend for Verici Dx's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Beginning Cash Position Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

17.75

10.34

9.81

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Beginning Cash Position	Get a 7-Day Free Trial			10.34	15.72	9.81	5.25	2.65

Verici Dx Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Verici Dx Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Verici Dx's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines